<SEC-DOCUMENT>0001973379-25-000077.txt : 20250304
<SEC-HEADER>0001973379-25-000077.hdr.sgml : 20250304
<ACCEPTANCE-DATETIME>20250304191429
ACCESSION NUMBER:		0001973379-25-000077
CONFORMED SUBMISSION TYPE:	144/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250304
DATE AS OF CHANGE:		20250304

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TEVA PHARMACEUTICAL INDUSTRIES LTD
		CENTRAL INDEX KEY:			0000818686
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	001-16174
		FILM NUMBER:		25707686

	BUSINESS ADDRESS:	
		STREET 1:		TEVA PHARMACEUTICAL INDUSTRIES LIMITED
		STREET 2:		124 DVORA HANEVI'A ST.
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6944020
		BUSINESS PHONE:		972 (3) 914-8213

	MAIL ADDRESS:	
		STREET 1:		TEVA PHARMACEUTICAL INDUSTRIES LIMITED
		STREET 2:		124 DVORA HANEVI'A ST.
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6944020

REPORTING-OWNER:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			McAvoy David R.
		CENTRAL INDEX KEY:			0001758842
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		144/A

	MAIL ADDRESS:	
		STREET 1:		C/O ENDOCYTE, INC., 3000 KENT AVENUE
		STREET 2:		SUITE A1-100
		CITY:			WEST LAFAYETTE
		STATE:			IN
		ZIP:			47906
</SEC-HEADER>
<DOCUMENT>
<TYPE>144/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144/A</submissionType>
    <previousAccessionNumber>0001973379-25-000075</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001758842</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0000818686</issuerCik>
      <issuerName>TEVA PHARMACEUTICAL INDUSTRIES LTD</issuerName>
      <secFileNumber>001-16174</secFileNumber>
      <issuerAddress>
        <com:street1>TEVA PHARMACEUTICAL INDUSTRIES LIMITED</com:street1>
        <com:street2>124 DVORA HANEVI'A ST.</com:street2>
        <com:city>TEL AVIV</com:city>
        <com:stateOrCountry>L3</com:stateOrCountry>
        <com:zipCode>6944020</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>972 (3) 914-8213</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>McAvoy David R.</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Officer</relationshipToIssuer>
        <relationshipToIssuer>EVP CHIEF LEGAL OFFICER</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>ORDINARY SHARES</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>CITIGROUP GLOBAL MARKETS</name>
        <address>
          <com:street1>390 GREENWICH ST</com:street1>
          <com:city>NEW YORK</com:city>
          <com:stateOrCountry>NY</com:stateOrCountry>
          <com:zipCode>10013</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>4827</noOfUnitsSold>
      <aggregateMarketValue>77232.00</aggregateMarketValue>
      <noOfUnitsOutstanding>1133838689</noOfUnitsOutstanding>
      <approxSaleDate>03/04/2025</approxSaleDate>
      <securitiesExchangeName>NYSE</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>ORDINARY SHARES</securitiesClassTitle>
      <acquiredDate>03/04/2024</acquiredDate>
      <natureOfAcquisitionTransaction>RESTRICTED STOCK UNIT VESTING</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>TEVA PHARMACEUTICAL INDUSTRIES LIMITED</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>16741</amountOfSecuritiesAcquired>
      <paymentDate>03/04/2025</paymentDate>
      <natureOfPayment>COMPENSATION</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <remarks>3 D BASED ON INDICATIVE PRICE OF 16
SHARES WERE SOLD PURSUANT TO A TRADING PLAN DATED NOV 15 2024</remarks>
    <noticeSignature>
      <noticeDate>03/04/2025</noticeDate>
      <planAdoptionDates>
        <planAdoptionDate>11/15/2024</planAdoptionDate>
      </planAdoptionDates>
      <signature>CONFORMED SIGNATURE ON FILE</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
